The Atmo® Gas Capsule a world-first ingestible gas-sensing capsule to provide unique insights into gut health and microbiome function.

The gas-sensing capsule assesses the functional health of a patient’s entire gastrointestinal system and aims to provide: better diagnosis, more targeted and personalized treatment, earlier relief of symptoms and improved healthcare outcomes.

The capsule can electronically report important data by continuously detecting gases and wirelessly transmitting the data to provide insights into the location of the capsule, microbiome function and gastrointestinal health.

The ingestible capsule offers a potential diagnostic tool for many disorders of the gut from motility disorders, IBS and IBD to liver disease.

The Atmo Gas Capsule is currently an investigational device exclusively for use in clinical investigations, and is not available for sale.

Gut disorders are common and debilitating

Gut disorders are one of the most common ailments in the world affecting tens of millions of people.
These disorders include motility abnormalities, SIBO, IBS and IBD. Gases are important biomarkers of disease, dysfunction and dysbiosis.


40% of global population suffer from a Functional Gastrointestinal Disorder (FGID).


30% of patients remain undiagnosed and suffer from the recurrence of disorders.


IBS affects 25 to 45 million people in the USA and 2 to 5 million in Australia.


GI disorders and disease treatment market (2013 USD).

How the Atmo Gas Capsule works

The vitamin-sized electronic capsule measures gaseous biomarkers at the source of production as it passes through the gastrointestinal system. This data is continuously transmitted to a pocket-sized receiver, and sent to the cloud for aggregation, analysis, and diagnosis.

The gas sensors are sealed within a special membrane that allows gas in but keeps out stomach acid and digestive juices.

The capsule aims to determine transit times derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of oxygen capsule tumble, and antenna reflectance.

Media coverage
Medical Advisory Board

Prof. Eamonn Quigley (Chair)

David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology.
Houston Methodist Hospital

Professor Peter Gibson

Prof. Peter Gibson

Affiliated with
Monash University

Prof William D. Chey

Prof. William D. Chey

Chief of Gastroenterology and Hepatology.
University of Michigan

Prof. Satish Rao

Prof. Satish Rao

Distinguished University Chair in Gastroenterology & Professor of Medicine. Director, Neurogastroenterology/Motility and Digestive Health Clinical Research Center.
Augusta University

Prof. Lin Chang

Prof. Lin Chang

Professor of Medicine, Vice-Chief of the Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine.
David Geffen School of Medicine at UCLA

Prof. Anthony Lembo

Prof. Anthony Lembo

Director of Research for Digestive Disease & Surgery Institute.
Cleveland Clinic

Dr Braden Kuo

Assoc. Prof. Braden Kuo

Director of Center for Neurointestinal Health at Massachusetts General Hospital and Associate Professor at Harvard Medical School.

Malcolm Hebblewhite

Malcolm Hebblewhite

President & CEO, Co-Founder

Kate Hill

Kate Hill

Chair of the Board & Non-Executive Director

Chris Roberts

Dr. Chris Roberts AO

Non-Executive Director

Chris Bertrand

Chris Bertrand

Non-Executive Director

Dr Kyle Berean

Dr. Kyle Berean

Head of Clinical Affairs & Co-Founder

James John

Dr. James John

Head of Research and Development/Product Development & Co-Founder

Dr Carl Runde

Dr. Carl Runde

Chief Financial Officer & Company Secretary

Sue Dafnias

Sue Dafnias

Head of Commercial

Adam Chrimes

Dr. Adam Chrimes

Core Technology Lead & Co-Founder

Tajanka Mladenovska

Quality Assurance/Regulatory Affairs Manager

Matt Reeves

Manufacturing Manager

Prof Kourosh Kalantar zadeh

Professor Kourosh Kalantar-zadeh

Lead Scientific Advisor